FMP
Biogen Inc.
BIIB
NASDAQ
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
119.03 USD
0.19 (0.16%)
Latest BIIB News
Danny Green
Feb 13, 2025
Biogen Inc. (NASDAQ:BIIB) Price Target and Earnings Insight
On February 13, 2025, Sumant Kulkarni from Canaccord Genuity set a price target of $265 for Biogen Inc. (NASDAQ:BIIB). At the time, the stock was priced at $138.06, suggesting a potential increase of about 91.95%. Biogen, a biotechnology company, focuses on discovering, developing, and delivering therapies for neurological diseases. It competes with companies like Roche and Novartis. Biogen recently reported strong fourth-quarter earnings, with an adjusted earnings per share (EPS) of $3.44, a 1...
Davit Kirakosyan
Feb 12, 2025
Biogen Shares Fall 4% as Weak Outlook Overshadows Q4 Earnings Beat
Biogen (NASDAQ:BIIB) delivered better-than-expected fourth-quarter earnings, but shares fell more than 4% intra-day after the company issued a lackluster 2025 outlook that signaled ongoing revenue pressures. For Q4 2024, Biogen reported adjusted earnings per share of $3.44, narrowly beating analyst expectations of $3.41. Revenue reached $2.5 billion, exceeding the forecasted $2.41 billion and reflecting a 3% year-over-year increase. However, full-year 2025 guidance disappointed investors. Biogen...
Alex Lavoie
Dec 9, 2024
Biogen Inc. Faces Challenges and Opportunities in Drug Development
Biogen Inc. (NASDAQ:BIIB) is a biotechnology company known for its focus on neurological diseases. It develops therapies for conditions like multiple sclerosis and Alzheimer's disease. Biogen faces competition from other biotech firms like Roche and Novartis. Recently, Singhal Priya, Biogen's Head of Development, sold 110 shares at $157.21 each, retaining 5,426 shares. Biogen's recent downgrade by Jefferies highlights challenges in its drug pipeline, particularly with Leqembi (lecanemab). Sales...
Davit Kirakosyan
Nov 18, 2024
Biogen Downgraded to Hold as Near-Term Growth Prospects Dim
Needham analysts downgraded Biogen (NASDAQ:BIIB) from Buy to Hold, citing limited upside potential for the stock over the next year. The decision was based on slower-than-expected growth from new products and a lack of significant pipeline developments in the near term. Leqembi, a key Alzheimer’s treatment in Biogen’s portfolio, was projected to grow at a slower pace, with physician feedback indicating a gradual adoption. As a result, the analysts lowered 2025 and 2026 Leqembi sales estimates, p...
Davit Kirakosyan
Nov 14, 2024
Citi Starts Neutral Coverage on Biogen Stock
Citi analysts initiated coverage on Biogen (NASDAQ:BIIB) with a Neutral rating and a price target of $190 on the stock. The assessment reflects a balance between the company’s recent launches and ongoing challenges in its legacy franchises. Biogen’s core revenue drivers, including its multiple sclerosis (MS) portfolio, Spinraza for spinal muscular atrophy (SMA), and anti-CD20 royalties, have faced prolonged declines. Over the past five years, these segments reported compound annual growth rate (...
Davit Kirakosyan
Oct 30, 2024
Biogen Posts Q3 Earnings Beat and Raises 2024 Guidance
Biogen (NASDAQ:BIIB) reported better-than-expected third-quarter results and raised its annual earnings guidance. The biotech firm posted Q3 earnings per share of $4.08, beating Wall Street expectations of $3.77, with revenue reaching $2.47 billion, slightly above the consensus of $2.43 billion. The company’s multiple sclerosis segment generated $1.05 billion in revenue, close to estimates, while sales of Biogen's Alzheimer’s drug Leqembi rose to $67 million from about $40 million in the prior q...
Zacks Investment Research
Aug 22, 2024
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reuters
Aug 22, 2024
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday.
Seeking Alpha
Aug 17, 2024
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is generating positive longer-term clinical data. Biogen's pipeline includes potential revenue contributors in Alzheimer's, Parkinson's, and kidney disease therapies, pain therapeutics and MS.
The Motley Fool
Aug 13, 2024
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.
